Licensing Agreement Allows CDI to Utilize ViaCyte’s Patented Technology for the Differentiation and Manufacture of iCell® Hepatocytes MADISON, WIS., April 13, 2011 – Cellular Dynamics International, Inc. (CDI), the world’s largest producer of tissue cells derived from human induced pluripotent stem cell (iPSC) lines, today announced it has strengthened its intellectual property (IP) portfolio by…
MADISON, WIS., April 7, 2011 – Cellular Dynamics International, Inc. (CDI), the world’s only industrial manufacturer of human induced pluripotent stem cells (iPSCs) and tissue cells, has closed on a $30 million private equity round. This recent Series B Preferred Stock financing was led by an entity affiliated with Tactics II Stem Cell Ventures, which along with its affiliates led CDI’s prior capital raises. Other investors in this financing round include Sam Zell’s Equity Group Investments LLC, Sixth Floor Investors LP and G Force Investments LLC. CDI has raised a total of $100 million since 2004.
SITTINGBOURNE, April 1, 2011 – Midas Mediscience Ltd (Midas) announced today that it is advancing the research collaboration with Cellular Dynamics International (CDI) to identify and predict drug-induced side effects in human induced pluripotent stem (iPS) cell-derived iCell® Cardiomyocytes. Midas, the life sciences company that acquired the business and assets of VivoMedica Ltd and the DrugPrint® technology originally developed by QinetiQ plc, is building on earlier collaborative work with CDI and their induced pluripotent stem (iPS) cell-derived iCell Cardiomyocytes.